PDS Biotechnology Corporation (PDSB)
| Market Cap | 11.80M -80.2% |
| Revenue (ttm) | n/a |
| Net Income | -33.67M |
| EPS | -0.64 |
| Shares Out | 55.97M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 837,666 |
| Open | 0.2152 |
| Previous Close | 0.2179 |
| Day's Range | 0.2080 - 0.2250 |
| 52-Week Range | 0.1952 - 1.5500 |
| Beta | 1.55 |
| Analysts | Strong Buy |
| Price Target | 5.75 (+2,626.41%) |
| Earnings Date | Aug 13, 2026 |
About PDSB
PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company’s lead product candidate is PDS0101, a Versamune HPV, which is in phase II clinical trial for the treatment of head and neck, cervical, anal, vaginal, vulvar, and penile cancers. It also develops various product candidates, which are in preclinical trials, including PDS0102, an investigational immunotherapy utilizing tumor-associated and immunologically active T cell receptor gamma... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 3 analysts, the average rating for PDSB stock is "Strong Buy." The 12-month stock price target is $5.75, which is an increase of 2,626.41% from the latest price.
News
PDS Biotechnology reports Q2 EPS (18c), consensus (13c)
The company said, “The Company’s cash balance as of June 30, 2026, was $5.6 million.”
PDS Biotechnology price target lowered to $7 from $15 at H.C. Wainwright
H.C. Wainwright lowered the firm’s price target on PDS Biotechnology (PDSB) to $7 from $15 and keeps a Buy rating on the shares. The company’s strategic shift was unexpected but…
PDS Biotech Reports Second Quarter 2026 Financial Results
PRINCETON, N.J., Aug. 13, 2026 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a clinical-stage biotechnology company focused on developing targeted ...
PDS Biotechnology Earnings release: Q2 2026
PDS Biotechnology released its Q2 2026 earnings on August 13, 2026, summarizing the period's financial results.
PDS Biotechnology Quarterly report: Q2 2026
PDS Biotechnology has published its Q2 2026 quarterly earnings report on August 13, 2026.
PDS Biotech Announces Strategic Refocus Prioritizing PDS0301 in Metastatic Colorectal Cancer (mCRC) and Partnership Strategy for PDS0101
PRINCETON, N.J., Aug. 11, 2026 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on developing targeted immu...
PDS Biotechnology Transcript: AGM 2026
The 2026 annual meeting was held virtually, covering director elections, governance amendments, auditor ratification, and executive compensation. All proposals passed, a quorum was confirmed, and no shareholder questions were raised. Forward-looking risks were acknowledged.
PDS Biotechnology registers to sell 13.32M shares of common stock for holders
This filing relates to the offer and sale from time to time by the selling stockholders of up to 13.32M shares of common stock. The company is not selling any…
PDS Biotechnology Registration statement: Registration filing
PDS Biotechnology filed a registration statement on July 10, 2026, providing details about a securities offering with the SEC.
PDS Biotechnology Proxy statement: Proxy filing
PDS Biotechnology filed a proxy statement on June 26, 2026, providing details for shareholder voting and corporate governance matters.
PDS Biotechnology Proxy statement: Proxy filing
PDS Biotechnology filed a proxy statement on June 26, 2026, providing details for shareholder voting and corporate governance matters.
PDS Biotechnology Proxy statement: Proxy filing
PDS Biotechnology filed a proxy statement on June 15, 2026, providing details for shareholder voting and corporate governance matters.
PDS Biotechnology Earnings Call Transcript: Q1 2026
Clinical programs advanced with protocol amendments expected to accelerate timelines and reduce costs. Net loss narrowed year-over-year, and new patents extend exclusivity into the 2040s. Additional data from colorectal cancer trials anticipated by year-end.
PDS Biotechnology Earnings release: Q1 2026
PDS Biotechnology released its Q1 2026 earnings on May 13, 2026, summarizing the period's financial results.
PDS Biotechnology Quarterly report: Q1 2026
PDS Biotechnology has published its Q1 2026 quarterly earnings report on May 13, 2026.
PDS Biotech Reports First Quarter 2026 Financial Results and Provides Clinical Programs and Corporate Update
Investor Webcast Scheduled for 8:00 am ET PRINCETON, N.J., May 13, 2026 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy co...
PDS Biotech Announces Conference Call and Webcast for 2026 First Quarter Financial Results
PRINCETON, N.J., May 06, 2026 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immu...
PDS Biotechnology Registration statement: Registration filing
PDS Biotechnology filed a registration statement on April 24, 2026, providing details about a securities offering with the SEC.
PDS Biotechnology Slides: Corporate presentation
PDS Biotechnology has posted slides in relation to its latest quarterly earnings report, which was published on April 22, 2026.
PDS Biotechnology announces positive Phase 2 trial data for PDS01ADC
PDS Biotechnology (PDSB) announced the publication of clinical and immunological biomarker data from Stage 1 of a Phase 2 trial evaluating its tumor-targeted IL-12 immunocytokine, PDS01ADC, in the Mar...
PDS Biotech Announces Publication of Positive PDS01ADC Interim Phase 2 Clinical Trial Data from Stage 1 of NCI-led Metastatic Colorectal Cancer (mCRC) Trial
78% Objective Response Rate (ORR) with PDS01ADC; Parallel trial without PDS01ADC had 35% ORR 2-year survival rate of >80%; Parallel trial without PDS01ADC resulted in 2-year survival rate of ~35%
PDS Biotechnology Earnings Call Transcript: Q4 2025
Clinical programs advanced with a key protocol amendment for faster regulatory submission in HPV-16 positive cancer. Net loss narrowed to $34.5M in 2025, with reduced operating expenses and strong cash position. New patents extend exclusivity into the 2040s.
PDS Biotechnology Annual report: Q4 2025
PDS Biotechnology has published its Q4 2025 annual report on March 30, 2026.
PDS Biotechnology Earnings release: Q4 2025
PDS Biotechnology released its Q4 2025 earnings on March 30, 2026, summarizing the period's financial results.
PDS Biotech Reports Full Year 2025 Financial Results and Provides Update on PDS0101 Phase 3 Program and PDS01ADC Clinical Advancement
Filed Phase 3 Amendment Incorporates PFS as Interim Primary Endpoint Expected to Shorten Trial Duration and Reduce Costs